慢性乙型肝炎的治疗—2009年及未来

帅庭

Treatment of Chronic Hepatitis B Infection - Year 2009 and Beyond
George KK Lau
Department of Medicine, The University of Hong Kong
On the second day of APASL, Professor George KK Lau gave a lecture on the treatment of chronic hepatitis B infection in 2009 and beyond. He said “We will need better therapy which will induce lasting off-treatment sustained disease remission.

This will mean sustained full hepatitis B e-antigen seroconversion or even hepatitis B surface antigen seroconversion. Being able to do this will shorten the duration of therapy and hence to avoid the cost, side effect and the risk of development of viral resistance with the use of prolonged nucleos(t)ide therapy.”

Otherwise, he pointed out that in order to facilitate better monitoring of anti-hepatitis B therapy, the development of standardized assay for serum viral antigen quantitation would be of great value

更多精彩内容请点击：http://apasl2009-cn.ihepa.com/17-170-2041.html

拜田八放斋

召唤英语达人～～～～

春波

原帖由 拜田八放斋 于 2009-2-26 18:50 发表
召唤英语达人～～～～

baw123

在APASL会议的第二天，George KK Lau教授做了题为“Treatment of Chronic Hepatitis B Infection - Year 2009 and Beyond”的大会报告。他指出我们需要更好的治疗方法以达到治疗结束后持久的病情缓解。这意味着需要达到乙肝e抗原血清学转换，甚至表面抗原血清学转换。从而可以缩短疗程，避免因长期应用核苷（酸）类药物而造成的费用、副作用及病毒耐药风险的增加。同时，为了更好的监测乙肝抗病毒治疗，血清病毒抗原定量的标准化检测方法的发展将有巨大价值。George KK Lau教授相信，在不久的将来，随着遗传学、免疫学及病毒学相关研究的发展，我们将能以个体化的形式进一步优化乙肝抗病毒治疗，并且联合治疗将得到更大发展。

baw123

On the second day of APASL, Professor George KK Lau gave a lecture on the treatment of chronic hepatitis B infection in 2009 and beyond. He said “We will need better therapy which will induce lasting off-treatment sustained disease remission.

This will mean sustained full hepatitis B e-antigen seroconversion or even hepatitis B surface antigen seroconversion. Being able to do this will shorten the duration of therapy and hence to avoid the cost, side effect and the risk of development of viral resistance with the use of prolonged nucleos(t)ide therapy.”

Otherwise, he pointed out that in order to facilitate better monitoring of anti-hepatitis B therapy, the development of standardized assay for serum viral antigen quantitation would be of great value.

In the end, he believed that in the very near future, based on advanced technology platform available for more detailed genetic, immunological and virological studies, we would be able to further optimize hepatitis B therapy in a personalized fashion, and a more rational basis for combination therapy would be developed.

在APASL会议的第二天，George KK Lau教授做了题为“Treatment of Chronic Hepatitis B Infection - Year 2009 and Beyond”的大会报告。他指出我们需要更好的治疗方法以达到治疗结束后持久的病情缓解。这意味着需要达到乙肝e抗原血清学转换，甚至表面抗原血清学转换。从而可以缩短疗程，避免因长期应用核苷（酸）类药物而造成的费用、副作用及病毒耐药风险的增加。同时，为了更好的监测乙肝抗病毒治疗，血清病毒抗原定量的标准化检测方法的发展将有巨大价值。George KK Lau教授相信，在不久的将来，随着遗传学、免疫学及病毒学相关研究的发展，我们将能以个体化的形式进一步优化乙肝抗病毒治疗，并且联合治疗将得到更大发展。

lazio13

说了半天没什么正经东西

拜田八放斋

有正经的东西 他就上自然 等着拿诺贝尔炸药奖了～～还在这无关痛痒的会上挠痒痒～～～

jiahuida

FORRESTFU

人家说话比较含蓄。

是这样，一直以来，医学界强调的是“持续抑制血清HBVDNA”，至于能否实现血清转换，并不是治疗的直接目标。

现在，一些有头有脸的人物也开始转向了。

说白了，治疗的目标，必须是表面抗原的血清转换，这是躲不过去的。